DOA
AZN icon

D'Orazio & Associates’s AstraZeneca AZN Stock Holding History

D'Orazio & Associates’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-174
Closed -$21K – 150
2021
Q3 		$21K Buy
+174
New +$20.3K 0.01% 378
2018
Q2 		– Sell
-68
Closed -$5K – 272
2018
Q1 		$5K Buy
+68
New +$4.71K ﹤0.01% 233

Other funds holding AZN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
GQG Partners
GQG Partners Ft. Lauderdale, Florida $53.8B AUM 19.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM

D'Orazio & Associates's AZN Position: Q4 2021 in Review

D'Orazio & Associates sold out of AstraZeneca (AZN) in Q4 2021, closing a stake of 174 shares — an estimated $21K sold.

D'Orazio & Associates first reported a position in AZN in Q1 2018 and held it in 2 quarters. The position peaked at $21K in Q3 2021. 949 funds tracked by Wall St. Rank hold AZN as of Q4 2021.

  • D'Orazio & Associates reported no remaining AstraZeneca position as of Q4 2021 after selling out during the quarter.
  • D'Orazio & Associates sold 174 AstraZeneca shares in Q4 2021, an estimated $21K.
  • D'Orazio & Associates first reported a position in AstraZeneca in Q1 2018 and held it in 2 quarters.
  • D'Orazio & Associates's AstraZeneca position peaked at $21K in Q3 2021.
  • 949 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2021.

Based on D'Orazio & Associates's 13F filing for Q4 2021, filed 7 Feb 2022.